Kadmon (KDMN) and Opiant Pharmaceuticals (NASDAQ:OPNT) Financial Comparison

Opiant Pharmaceuticals (NASDAQ: OPNT) and Kadmon (NYSE:KDMN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Risk and Volatility

How to Become a New Pot Stock Millionaire

Opiant Pharmaceuticals has a beta of -0.63, suggesting that its stock price is 163% less volatile than the S&P 500. Comparatively, Kadmon has a beta of 3.97, suggesting that its stock price is 297% more volatile than the S&P 500.

Earnings and Valuation

This table compares Opiant Pharmaceuticals and Kadmon’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $18.45 million 2.62 $6.58 million $2.94 7.00
Kadmon $12.26 million 25.14 -$79.77 million ($1.42) -2.76

Opiant Pharmaceuticals has higher revenue and earnings than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

4.2% of Opiant Pharmaceuticals shares are held by institutional investors. Comparatively, 61.7% of Kadmon shares are held by institutional investors. 63.8% of Opiant Pharmaceuticals shares are held by company insiders. Comparatively, 8.4% of Kadmon shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Opiant Pharmaceuticals and Kadmon’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals -384.42% -403.59% -145.89%
Kadmon -650.47% N/A -110.26%

Analyst Ratings

This is a summary of current ratings and price targets for Opiant Pharmaceuticals and Kadmon, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 0 0 N/A
Kadmon 1 0 3 0 2.50

Kadmon has a consensus target price of $13.25, suggesting a potential upside of 238.01%. Given Kadmon’s higher probable upside, analysts clearly believe Kadmon is more favorable than Opiant Pharmaceuticals.

Summary

Kadmon beats Opiant Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.

Kadmon Company Profile

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. Its lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase II clinical studies for use in the treatment of non-small cell lung cancer and glioblastoma, as well as for treating autosomal dominant polycystic kidney disease; and KD034 that is used for the treatment of Wilson's disease, a genetic liver disease. Kadmon Holdings, Inc. has a strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; VIVUS, Inc.; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply